MDT

87.86

-1.21%↓

VEEV

221.66

-2.12%↓

A

109.71

-5.41%↓

HQY

82.88

-6.59%↓

PDCO

31.2

-0.22%↓

MDT

87.86

-1.21%↓

VEEV

221.66

-2.12%↓

A

109.71

-5.41%↓

HQY

82.88

-6.59%↓

PDCO

31.2

-0.22%↓

MDT

87.86

-1.21%↓

VEEV

221.66

-2.12%↓

A

109.71

-5.41%↓

HQY

82.88

-6.59%↓

PDCO

31.2

-0.22%↓

MDT

87.86

-1.21%↓

VEEV

221.66

-2.12%↓

A

109.71

-5.41%↓

HQY

82.88

-6.59%↓

PDCO

31.2

-0.22%↓

MDT

87.86

-1.21%↓

VEEV

221.66

-2.12%↓

A

109.71

-5.41%↓

HQY

82.88

-6.59%↓

PDCO

31.2

-0.22%↓

Search

Supernus Pharmaceuticals Inc

Open

SectorHealthcare

32.64 -0.12

Overview

Share price change

24h

Current

Min

31.94

Max

32.89

Key metrics

By Trading Economics

Income

-23M

15M

Sales

-1.5M

174M

P/E

Sector Avg

24.811

63.778

EPS

0.548

Profit margin

8.801

Employees

674

EBITDA

-20M

45M

Recommendations

By TipRanks

Recommendations

Buy

12 Months Forecast

+18.22% upside

Dividends

By Dow Jones

Next Earnings

7 May 2025

Market Stats

By TradingEconomics

Market Cap

-272M

1.8B

Previous open

32.76

Previous close

32.64

News Sentiment

By Acuity

16%

84%

28 / 386 Healthcare

Technical Score

By Trading Central

Confidence

Bullish Evidence

Supernus Pharmaceuticals Inc Chart

Past performance is not a reliable indicator of future results.

Related News

8 Apr 2024, 18:04 UTC

Major Market Movers

Supernus Pharmaceuticals Shares Slip 6.9% After FDA Says Drug Application Not Ready

Peer Comparison

Price change

Supernus Pharmaceuticals Inc Forecast

Price Target

By TipRanks

18.22% upside

12 Months Forecast

Average 38.8 USD  18.22%

High 44 USD

Low 36 USD

Based on 5 Wall Street analysts offering 12 month price targets forSupernus Pharmaceuticals Inc - Dist in the last 3 months.

Rating Consensus

By TipRanks

Buy

5 ratings

2

Buy

3

Hold

0

Sell

Technical Score

By Trading Central

32.3399 / 32.9Support & Resistance

Short Term

Bullish Evidence

Intermediate Term

Strong Bearish Evidence

Long Term

Weak Bearish Evidence

Sentiment

By Acuity

28 / 386 Healthcare

News Sentiment

Very Strong Bullish Evidence

Volatility

Below average

News Volume (RCV)

Below average

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

$

About Supernus Pharmaceuticals Inc

Supernus Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. The company's commercial products are Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prophylaxis of migraine headache; and Oxtellar XR, an extended release oxcarbazepine for the monotherapy treatment of partial onset seizures in adults and children between 6 to 17 years of age. It also offers comprise Qelbree, a novel non-stimulant indicated for the treatment of attention-deficit hyperactivity disorder (ADHD) in adults and pediatric patients 6 years and older; APOKYN for the acute intermittent treatment of hypomobility or off episodes in patients with advanced Parkinson's Disease (PD); XADAGO for treating levodopa/carbidopa in patients with PD experiencing off episodes; MYOBLOC, a Type B toxin product indicated for the treatment of cervical dystonia and sialorrhea in adults; GOCOVRI for the treatment of dyskinesia in patients with PD; and Osmolex ER for the treatment of Parkinson's disease and drug-induced extrapyramidal reaction in adult patients. In addition, the company's product candidates include SPN-830, a late-stage drug/device combination product candidate for the treatment of off episodes in PD patients; SPN-817, a novel first-in-class selective acetylcholinesterase inhibitor, which is in Phase II clinical trials for the treatment of epilepsy; SPN-820, a product candidate in Phase II clinical trials for treating resistant depression; SPN-443, a preclinical product for the treatment of ADHD/CNS; and SPN-446 for narcolepsy and SPN-448 for the treatment of CNS which is in discovery stage. It markets and sells its products through pharmaceutical wholesalers, specialty pharmacies, and distributors. Supernus Pharmaceuticals, Inc. was incorporated in 2005 and is headquartered in Rockville, Maryland.